Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML)

Leukemia Research

Volumn 20, Issue 2, 1996, Pages 175-180

  Samdani, Attique ^a   Vijapurkar, Ujjwala ^a   Grimm, Martha A ^a   Spier, Catherine S ^a   Grogan, Thomas M ^a   Glinsmann Gibson, Betty J ^a   List, Alan F ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

AML; CD 34; Cytogenetics; P glycoprotein

Indexed keywords

CD34 ANTIGEN; CYTARABINE; DAUNORUBICIN; GLYCOPROTEIN P; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHROMOSOME 16; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CYTOGENETICS; FEMALE; GENDER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 0029869917     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/0145-2126(95)00134-4     Document Type: Article

References (25)

1. Rees J. K. H., Gray R. G., Swirsky D. & Hayhoe F. G. J. (1986) Principal results of the medical research council's 8th acute myeloid leukemia trial. Lancet ii, 1236.
2. Bloomfield C. D., Goldman A., Hassfeld D. & Chapelle A. de la (1994) Fourth International Workshop on Chromosomes in Leukemia, 1982. Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet. Cytogenet. 11, 332.
3. Geller R. B., Zahurak M., Hurowitz C. A., Burke P. J., Karp J. E., Piantadosi S. & Civin C. I. (1990) Prognostic importance of immunophenotyping in adults with acute myelocytic leukemia: the significance of stem cell glycoprotein CD-34 (My10). Br. J. Haematol. 76, 340.
4. Hoyle C. F., Bastos M. de, Wheatley K., et al. (1989) AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. Br. J. Haematol. 72, 45.
5. Campos L., Guyotat D., Archibald E., et al. (1993) Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood 79, 473.
6. Pirker R., Wallner J., Geissler K., et al. (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. natn. Cancer Inst. 83, 708.
7. List A. F. (1993) Multidrug resistance: clinical relevance in acute leukemia. Oncology 7, 23.
8. List A. F., Spier C. M., Cline A., et al. (1991) Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br. J. Haematol. 78, 28.
9. + patients more frequently achieve CR with high dose cytosine arabinoside. Proc. Am. Soc. Clin. Oncol. 11, 262a.
10. + acute myeloid leukemia cells. Blood 82, 3157.
11. Marie J.-P., Zittoun R. & Sikic B. I. (1991) Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78, 586.
12. Mitelman F., Ed. (1991) ISCN guideline for cancer cytogenetics. Supplement to: An International System for Human Cytogenetic Nomenclature VI. Karger, Basel.
13. Samuels B. I., Larson R. A., Le Beau M. M., et al. (1988) Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vitro. Leukemia 2, 79.
14. Grogan T., Dalton W. S., Rybski J., et al. (1990) Optimization of immunocytochemical P-glycoprotein assessment in multidrug resistant plasma cell myeloma using three antibodies. Lab. Invest. 63, 815.
15. Kaplan E. L. & Meier P. (1958) Non parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457.
16. Paietta E., Andersen J., Racevskis J., Gallagher R., Bennett J., Yunis J., Cassileth P. & Wiernik P. H. (1994) Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analysis. Leukemia 8, 968.
17. Avvisati G., Mandelli F., Petti M. C., Vegna M. L., Spadea A., Liso V., Specchia G., Bernasconi C., Alessandrino E. P., Piatti C. & Carella A. M. (1990) Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group FIMEMA. Eur. J. Hematol. 44, 257.
18. Fenaux P., Tertian G., Castaigne S., Tilly H., Leverger G., Guy H., Bordessoule D., Leblay R., LeGall E., Colombat P., Tchernia G., Bauters F. & Marty M. (1991) A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. J. Clin. Oncol. 9, 1556.
19. Head D. R., Kopecky K. J., Willman C. & Appelbaum F. R. (1994) Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience. Leukemia 8(Suppl. 2), S38.
20. Wood P., Burgess R., MacGregor A. & Yin L. A. (1994) P-glycoprotein expression on acute myeloid leukemia blast cells at diagnosis predict response to chemotherapy and survival. Br. J. Haematol. 87, 509.
21. Lacombe F., Belloc F., Dumain P., Pintous M., Makhoul P. C., Saux M. C., Bernard P., Boisseau M. R. & Reiffers J. (1994) Detection of cytarabine resistance in patients with acute myelogenous leukemia using flow cytometry. Blood 84, 716.
22. Estey E. H., Keating M. J., McCredie K. B., Freireich E. J. & Plunkett W. (1990) Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia 4, 95.
23. Cole S. P. C., Bhardwaj G., Gerlach J. H., et al. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650.
24. r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 53, 1475.
25. List A. F., Spier C. S., Abbaszadegan M., Grogan T. M., Greer J. P., Wolff S. N., Scheper R. J. & Dalton W. S. (1993) Non-P-glycoprotein mediated multidrug resistance: identification of a novel drug resistance phenotype with prognostic relevance in acute myeloid leukemia. Blood 82(Suppl. 1), 443a.